Polmacoxib

Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase[1]. Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models[2].

Product Specifications

CAS Number

[301692-76-2]

Product Name Alternative

CG100649

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Carbonic Anhydrase; COX

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/polmacoxib.html

Purity

99.70

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(C(OC2(C)C)=C(C3=CC=CC(F)=C3)C2=O)C=C1)(N)=O

Molecular Formula

C18H16FNO4S

Molecular Weight

361.39

Precautions

H315, H319

References & Citations

[1]Kim SH, et al. CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs. 2014;32 (6) :1105-1112.|[2]Flick AC, et al. Synthetic Approaches to the New Drugs Approved During 2015 [published correction appears in J Med Chem. 2017 Oct 26;60 (20) :8680]. J Med Chem. 2017;60 (15) :6480-6515.